Association between Statin Use and Survival in Cancer Patients with Brain Metastasis: Retrospective Analysis from the Chinese Population.
Association between Statin Use and Survival in Cancer Patients with Brain Metastasis: Retrospective Analysis from the Chinese Population.
复制标题
DOI：
10.3390/ph15121474
复制
发表时间：
2022-11-26
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
脑转移预示着癌症患者更糟糕的临床结果。新出现的观察性证据表明，他汀类药物的使用在整体癌症预防中具有保护作用。他汀类药物是否也可以作为晚期癌症的辅助治疗仍在研究和争议中。选取2010年10月至2019年7月华西医院相关电子医疗记录中脑转移肿瘤患者的数据。使用Fisher精确卡方检验来比较队列之间的差异。在评估他汀类药物使用对脑转移癌患者总生存期（OS）的影响时，采用多因素Cox分析来调整潜在混杂因素。本回顾性研究纳入了4510例脑转移患者。患者总体他汀类药物使用率为5.28%（219例/4510例）。与未使用他汀类药物的队列相比，接受他汀类药物治疗的患者入院时Karnofsky表现评分（KPS, p < 0.001）降低，高密度脂蛋白（HDL, p = 0.020）降低，但体重指数（BMI, p = 0.002）和甘油三酯（TG, p < 0.001）升高。在单因素分析中，他汀类药物的使用与脑转移癌患者的OS无相关性(风险比（HR) = 0.90, 95%可信区间（CI）： 0.73-1.07, p = 0.213）。然而，在调整基线患者特征、代谢指标和癌症特异性因素后，他汀类药物的使用显示出显著的保护作用，有助于脑转移癌患者的生存（调节值r = 0.82, 95%CI: 0.69-0.99, p = 0.034）。我们的研究结果强调，他汀类药物在脑转移的癌症患者中显示出显著的生存益处。然而，需要进一步的研究来验证我们的发现。
Brain metastasis predicts a worse clinical outcome in cancer patients. Emerging observational evidence suggests that statin use has a protective role in overall cancer prevention. Whether statin use could also be a supplementary treatment for advanced-stage cancers remains under researched and controversial. Data for cancer patients with brain metastasis were selected from the linked electronic medical care records of the West China Hospital between October 2010 and July 2019. Fisher’s exact chi-square test was used to compare the differences between cohorts. Multivariate Cox analysis was conducted to adjust the potential confounders in evaluating the role of statin use in the overall survival (OS) of cancer patients with brain metastasis. There were 4510 brain metastatic patients included in this retrospective study. The overall statin use rate in our patients was 5.28% (219 cases/4510 cases). Compared with the non-statin use cohort, patients who received statin therapy showed a decreased Karnofsky performance score (KPS, p < 0.001) and lower high-density lipoprotein (HDL, p = 0.020) but higher body mass index (BMI, p = 0.002) and triglyceride (TG, p < 0.001) at admission. There was no association between statin use and the OS of the cancer patients with brain metastasis (Hazard ratio (HR) = 0.90, 95% confidence interval (CI): 0.73–1.07, p = 0.213) during the univariate analysis. However, after adjusting for baseline patient characteristics, metabolism indicators, and cancer-specific factors, statin use was shown to have a significant protective role, aiding the survival of the cancer patients with brain metastasis (adjustHR = 0.82, 95%CI: 0.69–0.99, p = 0.034). Our results highlight that statin use shows significant survival benefits in cancer patients with brain metastasis. However, future research is needed to validate our findings.
登录
查看更多内容
影响因子：
168.9
作者：
Renehan, Andrew G.;Tyson, Margaret;Zwahlen, Marcel
通讯作者：
Zwahlen, Marcel
DOI：
10.5114/aoms/123225
发表时间：
2022
期刊：
Archives of medical science : AMS
影响因子：
--
作者：
Amin F;Fathi F;Reiner Ž;Banach M;Sahebkar A
通讯作者：
Sahebkar A
影响因子：
51.1
作者：
Goldberg, Sarah B.;Schalper, Kurt A.;Kluger, Harriet M.
通讯作者：
Kluger, Harriet M.
影响因子：
2
作者：
Lakatos, E
通讯作者：
Lakatos, E
影响因子：
8.8
作者：
Luttman JH;Hoj JP;Lin KH;Lin J;Gu JJ;Rouse C;Nichols AG;MacIver NJ;Wood KC;Pendergast AM
通讯作者：
Pendergast AM